<SEC-DOCUMENT>0001193125-26-111262.txt : 20260317
<SEC-HEADER>0001193125-26-111262.hdr.sgml : 20260317
<ACCEPTANCE-DATETIME>20260317172943
ACCESSION NUMBER:		0001193125-26-111262
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260317
DATE AS OF CHANGE:		20260317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORASURE TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001116463
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				364370966
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16537
		FILM NUMBER:		26763672

	BUSINESS ADDRESS:	
		STREET 1:		220 E FIRST ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
		BUSINESS PHONE:		5036416115

	MAIL ADDRESS:	
		STREET 1:		220 E FIRST ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d108283ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy
Statement Pursuant to Section&nbsp;14(a) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&#8194;&#9744;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>OraSure Technologies, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of the Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g108283g52q14.jpg" ALT="LOGO" STYLE="width:2.41042in;height:0.73125in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from
Altai Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Commercial Milestones Approaching in 2026 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Highlights Extensive Engagement with Altai </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>for Its Founder to Force an <FONT STYLE="white-space:nowrap">Ill-Timed</FONT> Sale Process </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BETHLEHEM, PA., March</B><B></B><B>&nbsp;17, 2026 &#8212; </B>OraSure Technologies, Inc. (&#8220;OraSure&#8221; and the &#8220;Company&#8221;) (NASDAQ:
OSUR), a leader in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-need</FONT></FONT> and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital&#8217;s
March&nbsp;17, 2026, letter: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">OraSure&#8217;s Board and management team are steadfast in our commitment to driving value and acting in the
best interests of all shareholders through disciplined execution and rigorous oversight. Rishi Bajaj, Altai&#8217;s founder and principal, is pursuing a campaign that centers on his demand for a Board appointment to compel OraSure to sell itself
just as the Company is at an important inflection point with a series of regulatory and commercial milestones ahead in 2026. We cannot ask our shareholders to forego significant value upside to appease Mr.&nbsp;Bajaj, who is seeking to derail the
Company&#8217;s strategy in the middle of its execution and is unwilling to pursue a constructive resolution to his proxy contest. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">OraSure
continues to successfully execute a focused strategy designed to improve operating performance, strengthen margins, and position the business for revenue acceleration and long-term value creation by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Driving a Strategy for Growth in 2026</B>. Building on the strategic progress made throughout 2025, OraSure is
positioned to return to revenue growth in 2026 as our core <FONT STYLE="white-space:nowrap">end-markets</FONT> stabilize and clinical adoption of precision medicine strengthens. We expect this growth inflection to be further accelerated by the
anticipated commercial launch and <FONT STYLE="white-space:nowrap">scale-up</FONT> of high-impact products including the Sherlock<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> rapid molecular self-test for <I>Chlamydia
trachomatis</I>&nbsp;and<I>&nbsp;Neisseria gonorrhoeae</I>&nbsp;(CT/NG) and the <FONT STYLE="white-space:nowrap">Colli-Pee</FONT><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> <FONT STYLE="white-space:nowrap">at-home</FONT> urine
collection device for sexually transmitted infections (STIs), which target a combined $2&nbsp;billion addressable market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advancing Our Innovation Roadmap</B>. OraSure is focused on high-growth opportunities&nbsp;and their
anticipated paths to commercialization and revenue realization. At the end of 2025, OraSure submitted two separate product applications to the U.S. Food and Drug Administration for clearance of our rapid molecular self-test for&nbsp;CT/NG as well as
<FONT STYLE="white-space:nowrap">Colli-Pee</FONT><SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>. These milestones position OraSure for regulatory decisions, product launches and commercialization
<FONT STYLE="white-space:nowrap">ramp-up,</FONT> revenue growth, and profitability improvement in 2026. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Reducing Costs and Structurally Improving Margins Through Decisive Operational Actions.</B> Since late 2022,
OraSure has transformed our operational profile to position the Company to convert our manufacturing scale into long-term shareholder value and become a high-margin diagnostic leader. We have reduced our global workforce by approximately 40%, closed
four global sites, consolidated production into our Pennsylvania footprint, <FONT STYLE="white-space:nowrap">in-sourced</FONT> manufacturing, and wound down two declining product lines. These actions have reduced annual SG&amp;A expense (excluding
R&amp;D) by 37% since 2022 and contributed to ~260 basis points of adjusted gross margin expansion over the past three years, with a credible path toward 50% gross margin as scale and product mix improve. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Executing a Balanced and Disciplined Capital Allocation Strategy. </B>OraSure&#8217;s capital allocation
prioritizes <FONT STYLE="white-space:nowrap">high-ROI</FONT> growth while maintaining a debt-free balance sheet and returning capital to shareholders. This includes a $40&nbsp;million share repurchase program, signaling confidence in the
Company&#8217;s earnings potential and improving free cash flow profile. With a robust cash position, OraSure maintains significant optionality to pursue disciplined acquisitions and strategic partnerships that enhance our portfolio while continuing
to invest in R&amp;D targeting high-value growth markets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Demonstrating Conviction in Value Creation Strategy and Alignment.</B> Our leadership team has reiterated its
belief in the potential ahead for OraSure and our transformation strategy. In 2025, CEO Carrie Eglinton Manner and CFO Kenneth McGrath made significant open-market purchases of OraSure stock. These personal investments are continuing in 2026 under
Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, underscoring their confidence in the Company&#8217;s upcoming 2026 product launches and strategic roadmap. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>The Right Board to Oversee the Next Phase of Value Creation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Over the last six years, OraSure&#8217;s entire Board has been refreshed. We have added three new, highly qualified, independent directors
since 2023 with relevant industry expertise, including accomplished healthcare investor and shareholder advocate Steven K. Boyd in October 2025. The Board appointed John P. Kenny, who has served as a director since September 2024, as its Chair in
October 2025. Our Board also benefits from the deep financial and operational experience of Robert W. McMahon, CFO of West Pharmaceutical Services, Inc., who joined the Board in July 2023. Today, OraSure maintains a strong, independent, and fully
engaged Board that is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> with directors who have extensive backgrounds in healthcare and diagnostics along with capital markets and investor perspectives
plus executive-level experience to provide rigorous oversight as management positions the Company to return to growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Extensive
Engagement with Altai Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">OraSure&#8217;s Board has been routinely engaging with Altai for over a year and working diligently to
reach a constructive resolution to Altai&#8217;s demands. Throughout our engagement, Mr.&nbsp;Bajaj has been unfocused and vague with regards to his suggested actions to generate shareholder value and justify his demand for appointment to the Board.
Still, OraSure has consistently remained open and available to hearing and considering ideas from Altai. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has proposed, through multiple settlement offers, constructive solutions to
reach a compromise and avoid a proxy contest. The Company&#8217;s most recent settlement proposals have included: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Commitment to Appoint Altai&#8217;s Director Nominee, Mr.</B><B></B><B>&nbsp;Bertrand: </B>Following
Altai&#8217;s nominations of Mr.&nbsp;Bajaj and John Bertrand, whom Altai originally presented to the Company as an independent director candidate, the Board undertook a thorough evaluation of both candidates as well as other independent candidates
who were sourced through the Company&#8217;s nationally recognized director recruiting firm. Following that process and Altai&#8217;s insistence that no settlement could be reached without appointing an Altai nominee, OraSure ultimately proposed to
appoint Mr.&nbsp;Bertrand to the Board ahead of the Annual Meeting on the basis that he would be a fully independent director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Consulting and Information-Sharing Agreement: </B>When the Company declined to seat Mr.&nbsp;Bajaj on the
Board but offered to accept Mr.&nbsp;Bertrand instead, Mr.&nbsp;Bajaj countered with an uncompromising demand to receive access to virtually all Board-level materials, either directly from the Company or through Mr.&nbsp;Bertrand as an Altai
representative on the Board. The Board proposed several compromise solutions, including a detailed consulting and information-sharing framework, subject to confidentiality provisions and a commitment that Mr.&nbsp;Bertrand serve as a fully
independent director. Mr.&nbsp;Bajaj refused all of these offers, insisting that if Mr.&nbsp;Bertrand were to serve on the Board, he would act as Altai&#8217;s conduit for nearly unfettered access to all Board information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Commitment to Declassify the Board: </B>OraSure&#8217;s Board is committed to seeking shareholder approval for
a charter amendment to declassify the Board beginning in 2027 at the Annual Meeting. OraSure&#8217;s Board intends to put forth a proposal to declassify the Board at the Annual Meeting regardless of the outcome of negotiations with Altai.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OraSure will continue to take action that it believes protects the best interests of the Company and all our
shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evercore is serving as financial advisor, Goodwin Procter LLP is serving as legal advisor, and Joele Frank, Wilkinson Brimmer Katcher is
serving as strategic communications advisor to OraSure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About OraSure Technologies, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OraSure Technologies, Inc. (&#8220;OraSure&#8221; and &#8220;OTI&#8221;) transforms health through actionable insight and decentralizes diagnostics to connect
people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock
Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions.
OraSure&#8217;s portfolio of products is sold globally to clinical laboratories, hospitals, physicians&#8217; offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies,
and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains certain forward-looking statements. Forward-looking statements are not guarantees of future performance or results. Known and
unknown factors could cause actual performance or results to be materially different from those expressed or implied in these statements. Factors that could affect our results are discussed more fully in our SEC filings, including our registration
statements, Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2025, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers
should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure
Technologies undertakes no duty to update these statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OraSure intends to file a proxy statement and a white proxy card with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with
its solicitation of proxies for the Company&#8217;s 2026 annual meeting of stockholders (the &#8220;Annual Meeting&#8221;).<B>&nbsp;STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR
SUPPLEMENTS THERETO), THE ACCOMPANYING</B><B></B><B>&nbsp;WHITE</B><B></B><B>&nbsp;PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH, OR FURNISHED TO, THE SEC IN CONNECTION WITH THE ANNUAL MEETING CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME
AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING.</B>&nbsp;Stockholders will be able to obtain the Company&#8217;s proxy statement, any amendments or supplements to the proxy statement and other documents filed by the
Company with the SEC at no charge at the SEC&#8217;s website at<B><U>&nbsp;www.sec.gov</U></B>. Copies will also be available at no charge at the Company&#8217;s website
at<B><U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&nbsp;https://orasure.gcs-web.com/financial-information/sec-filings</FONT></FONT></U></B>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participant Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, each of its
directors (Carrie Eglinton Manner (Chief Executive Officer), Steven K. Boyd, Nancy J. Gagliano, M.D., M.B.A., John P. Kenny, Lelio Marmora and Robert W. McMahon) and one of its executive officers in addition to Ms. Eglinton Manner (Kenneth J.
McGrath, Chief Financial Officer) are deemed to be &#8220;participants&#8221; (as defined in Schedule 14A under the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company&#8217;s stockholders in connection with
matters to be considered at the Annual Meeting. Information about the names of the Company&#8217;s directors and officers, their respective interests in the Company by security holdings or otherwise, and their respective compensation is set forth in
the sections entitled &#8220;Executive Officers,&#8221; &#8220;Election of Directors,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Director Compensation,&#8221; and &#8220;Stock Ownership of Certain Beneficial Owners and
Management&#8221; in the Company&#8217;s definitive proxy statement on Schedule 14A for the Company&#8217;s 2025 Annual Meeting of Stockholders, filed with the SEC on April&nbsp;4, 2025 (available<U>&nbsp;here</U>). Supplemental information
regarding the participants&#8217; holdings of the Company&#8217;s securities can be found in SEC filings on Initial Statements of Beneficial Ownership of Securities on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC on
March&nbsp;27, 2025 for Mr. Kenny (available <U>here</U>); Mr. Marmora (available <U>here</U>), Mr. McMahon (available <U>here</U>), Ms. Gagliano (available <U>here</U>), and Mr. Kenny (available <U>here</U>); June&nbsp;5, 2025 for Ms. Eglinton
Manner (available <U>here</U>); June&nbsp;25, 2025 for Mr. Kenny (available <U>here</U>); August&nbsp;4, 2025 for Mr. McMahon (available <U>here</U>); August&nbsp;11, 2025 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for Mr. McGrath (available <U>here</U>); September&nbsp;26, 2025 for Mr. Kenny (available<U>&nbsp;here</U>&nbsp;and <U>here</U>); December&nbsp;2, 2025 for Ms. Gagliano (available <U>here</U>)
and Mr. Boyd (available <U>here</U>); December&nbsp;19, 2025 for Mr. Kenny (available <U>here </U>and <U>here</U>); on March&nbsp;3, 2026 for Mr. McGrath (available <U>here</U>) and Ms. Eglinton Manner (available <U>here</U>) and on March&nbsp;16,
2026 for Mr. McGrath (available <U>here</U>) and Ms. Eglinton Manner (available <U>here</U>). Such filings&nbsp;are also available on the Company&#8217;s website
at<U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&nbsp;https://orasure.gcs-web.com/financial-information/sec-filings</FONT></FONT></U>. Updated information regarding the identity of participants, and their direct or indirect
interests, by security holdings or otherwise, will be set forth in the Company&#8217;s proxy statement on Schedule 14A and other materials to be filed with the SEC in connection with the Annual Meeting. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Investor Contact:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Media Contacts:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jason Plagman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amy Koch</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VP, Investor Relations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director, Corporate Communications</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">investorinfo@orasure.com</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">media@orasure.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Adam Pollack / Chloe Karp</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joele Frank, Wilkinson Brimmer Katcher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(212) <FONT STYLE="white-space:nowrap">355-4449</FONT></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g108283g52q14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g108283g52q14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !% .0# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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1 * "@ H * "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
